xRead - September 2022

Wise et al.

Page 435

Author Manuscript Author Manuscript Author Manuscript Author Manuscript TABLE X.A.4-5. Evidence for allergen immunotherapy for the treatment of asthma in the context of coexistent allergic rhinitis Study Year LOE Study design Study groups Clinical endpoint Conclusion Erekosima et al. 1822 2014 1a SR Systematic review of 61 RCTs (26 specifically asthma and rhinitis): 1 SCIT vs placebo; 2 SCIT vs pharmacotherapy 1 Asthma and rhinitis/ conjunctivitis symptoms; 2 Asthma and rhinitis/ conjunctivitis medication use; 3 Safety of SCIT 1 Symptoms reduced with SCIT; a 2 Medication use reduced with SCIT; a 3 Most adverse reactions mild. Lin et al. 1694 2013 1a SR Systematic review of 63 RCTs (SCIT and SLIT): 1 SLIT vs placebo; 2 SLIT vs pharmacotherapy 1 Asthma and rhinitis/ conjunctivitis symptoms; 2 Combined medication use plus symptoms 1 Symptoms reduced with SLIT; b 2 Medication plus symptom scores reduced with SLIT. b Marogna et al. 1678 2008 1b RCT Rhinitis with/without intermittent asthma (n = 216): 1 Pharmacotherapy; 2 Pharmacotherapy plus SLIT c Development of persistent asthma (not at baseline), symptom and medication scores, daily medication use, new sensitization Persistent asthma incidence lower with SLIT vs control. Methacholine-positive patients after 3 years reduced with SLIT. Lower symptom and medication scores with SLIT. Novembre et al. 1798 2004 1b RCT Rhinoconjunctivitis, no asthma (n = 97): 1 SLIT, maintenance 3 years; 2 Standard symptomatic treatment, no SLIT Symptoms, rescue medication use, development of asthma Rescue medication use reduced with SLIT. Relative risk of asthma after 3 years greater in control group vs SLIT. Möller et al. 1797 2002 1b RCT Rhinoconjunctivitis with or without asthma (n = 191): 1 SCIT; 2 Control (no injections) Development of asthma (if none at trial start), BHR by PC 20 , VAS of symptoms Asthma incidence greater in controls. BHR improved with SCIT after 1 year pollen season.

BHR increased with SCIT. No HDM IgE difference. Increased medication use and

visits with placebo. No difference in asthma incidence.

Decreased asthma medication use with SCIT. Improved atopy scores with SCIT. Asthma incidence nearly half with SCIT.

BHR by PD 20 , serum IgE levels, rescue medication use, additional visits for symptoms, development of asthma

Asthma and rhinitis medication use, positive HDM skin test, development of asthma

Grembiale et al. 1795 2000 1b DBRCT HDM AR and BHR to methacholine (n = 44): 1 SCIT; 2 Placebo Inal et al. 1825 2007 2b Open, nonrandomized, prospective, parallel group

HDM AR and/or mild-to-moderate asthma (n = 147): 1 SCIT;

Int Forum Allergy Rhinol . Author manuscript; available in PMC 2020 June 10.